bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S3 from Sex-specific associations between adiponectin and leptin signaling and pancreatic cancer survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: September 2024

Association between SNPs in the leptin receptor gene and pancreatic cancer mortality by sex
Supplementary Table S1 from Sex-specific associations between adiponectin and leptin signaling and pancreatic cancer survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: September 2024

Number of pancreatic cancer cases with available plasma adipokine levels and SNPs in adiponectin and leptin receptor genes
Table S3 from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: September 2024

Supplementary Table S3 shows a description (demographic and healthcare use characteristics) of eligible adults in intention-to-treat analysis sample, by study timepoint.
Table S2 from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: September 2024

Supplementary Table S2 shows when each intervention component was delivered, by study year.
Table S1 from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: September 2024

Supplementary Table S1 shows the text used for advance notifications (text messages and live phone calls) and reminders (automated phone calls), in English and Spanish.
Data from Patterns of evidence-based care for the diagnosis, staging, and first-line treatment of breast cancer by race-ethnicity: a SEER-Medicare study
Authors: Herbach Emma L. , Nash Sarah H. , Lizarraga Ingrid M. , Carnahan Ryan M. , Wang Kai , Ogilvie Amy C. , Curran Michaela , Charlton Mary E.
Published: September 2024

Abstract
Background: Racial and ethnic disparities in guideline-recommended breast cancer treatment are well documented, however studies including diagnostic and staging procedures necessary to determine treatment indications are lacking. The purpose of this study was to characterize patterns in delivery of evidence-based services for the diagnosis, clinical workup, and first-line treatment of breast cancer by race-ethnicity.

Methods: SEER-Medicare data were used to identify women diagnosed with invasive breast cancer between 2000 and 2017 at age 66 or older (n = 215,605). Evidence-based services included diagnostic procedures (diagnostic mammography and breast biopsy), clinical workup (stage and grade determination, lymph node biopsy, and HR and HER2 status determination), and treatment initiation (surgery, radiation, chemotherapy, hormone therapy, and HER2-targeted therapy). Poisson regression was used to estimate rate ratios (RRs) and 95% Confidence Intervals (CIs) for each service.

Results: Black and American Indian/Alaska Native (AIAN) women had significantly lower rates of evidence-based care across the continuum from diagnostics through first-line treatment compared to non-Hispanic White (NHW) women. AIAN women had the lowest rates of HER2-targeted therapy and hormone therapy initiation. While Black women also had lower initiation of HER2-targeted therapy than NHW, differences in hormone therapy were not observed.

Conclusions: Our findings suggest patterns along the continuum of care from diagnostic procedures to treatment initiation may differ across race-ethnicity groups.

Impact: Efforts to improve delivery of guideline-concordant treatment and mitigate racial-ethnic disparities in healthcare and survival should include procedures performed as part of the diagnosis, clinical workup, and staging processes.
Data from Racial and Ethnic Variation in Diagnostic Mammography Performance among Women Reporting a Breast Lump
Authors: Nyante Sarah J. , Abraham Linn , Aiello Bowles Erin J. , Lee Christoph I. , Kerlikowske Karla , Miglioretti Diana L. , Sprague Brian L. , Henderson Louise M.
Published: September 2024

AbstractBackground:
We evaluated diagnostic mammography among women with a breast lump to determine whether performance varied across racial and ethnic groups.
Methods:
This study included 51,014 diagnostic mammograms performed between 2005 and 2018 in the Breast Cancer Surveillance Consortium among Asian/Pacific Islander (12%), Black (7%), Hispanic/Latina (6%), and White (75%) women reporting a lump. Breast cancers occurring within 1 year were ascertained from cancer registry linkages. Multivariable regression was used to adjust performance statistic comparisons for breast cancer risk factors, mammogram modality, demographics, additional imaging, and imaging facility.
Results:
Cancer detection rates were highest among Asian/Pacific Islander [per 1,000 exams, 84.2 (95% confidence interval (CI): 72.0–98.2)] and Black women [81.4 (95% CI: 69.4–95.2)] and lowest among Hispanic/Latina women [42.9 (95% CI: 34.2–53.6)]. Positive predictive values (PPV) were higher among Black [37.0% (95% CI: 31.2–43.3)] and White [37.0% (95% CI: 30.0–44.6)] women and lowest among Hispanic/Latina women [22.0% (95% CI: 17.2–27.7)]. False-positive results were most common among Asian/Pacific Islander women [per 1,000 exams, 183.9 (95% CI: 126.7–259.2)] and lowest among White women [112.4 (95% CI: 86.1–145.5)]. After adjustment, false-positive and cancer detection rates remained higher for Asian/Pacific Islander and Black women (vs. Hispanic/Latina and White). Adjusted PPV was highest among Asian/Pacific Islander women.
Conclusions:
Among women with a lump, Asian/Pacific Islander and Black women were more likely to have cancer detected and more likely to receive a false-positive result compared with White and Hispanic/Latina women.
Impact:
Strategies for optimizing diagnostic mammography among women with a lump may vary by racial/ethnic group, but additional factors that influence performance differences need to be identified.

See related In the Spotlight, p. 1479
Data from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Authors: Van Loon Katherine , Mmbaga Elia J. , Mushi Beatrice P. , Selekwa Msiba , Mwanga Ally , Akoko Larry Onyango. , Mwaiselage Julius , Mosha Innocent , Ng Dianna L. , Wu Wei , Silverstein Jordyn , Mulima Gift , Kaimila Bongani , Gopal Satish , Snell Jeff M. , Benz Stephen C. , Vaske Charles , Sanborn Zack , Sedgewick Andrew J. , Radenbaugh Amie , Newton Yulia , Collisson Eric A.
Published: September 2024

Abstract
Background: Esophageal squamous cell carcinoma (ESCC) comprises 90% of all esophageal cancer cases globally and is the most common histology in low-resource settings. Eastern Africa has a disproportionately high incidence of ESCC.

Methods: We describe the genomic profiles of 61 ESCC cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We also provide a comparison to ESCC tumors in The Cancer Genome Atlas.

Results: We observed substantial transcriptional overlap with other squamous histologies via comparison with The Cancer Genome Atlas (TCGA) PanCan dataset. DNA analysis revealed known mutational patterns, both genome-wide as well as in genes known to be commonly mutated in ESCC. TP53 mutations were the most common somatic mutation in tumors from both Tanzania and Malawi but were detected at lower frequencies than previously reported in ESCC cases from other settings. In a combined analysis, two unique transcriptional clusters were identified: a proliferative/epithelial cluster and an invasive/migrative/mesenchymal cluster. Mutational signature analysis of the Tanzanian cohort revealed common signatures associated with aging and cytidine deaminase activity (APOBEC) and an absence of signature 29, which was previously reported in the Malawi cohort.

Conclusion: This study defines the molecular characteristics of ESCC in Tanzania, and enriches the Eastern African dataset, with findings of overall similarities but also some heterogeneity across two unique sites.

Impact:
Despite a high burden of ESCC in Eastern Africa, genomic investigations in this region are nascent. This represents the largest comprehensive genomic analysis ESCC from sub-Saharan Africa to date.
Data from Urine pH and Risk of Bladder Cancer in Northern New England
Authors: Fischer Alexander H. , Wong Jason YY. , Baris Dalsu , Koutros Stella , Karagas Margaret R. , Schwenn Molly , Johnson Alison , Alguacil Juan , Silverman Debra T. , Rothman Nathaniel
Published: September 2024

Abstract
Background:
Acidic urine pH is associated with rapid hydrolysis of N-glucuronide conjugates of aromatic amines into metabolites that may undergo metabolism in the bladder lumen to form mutagenic DNA adducts. We previously reported that consistently acidic urine was associated with increased bladder cancer risk in a hospital-based case-control study in Spain. Here, we conducted a separate study in northern New England to replicate these findings.
Methods:
In a large, population-based case-control study conducted in Maine, New Hampshire, and Vermont, we examined bladder cancer risk in relation to consistent urine pH, measured twice daily by participants over four consecutive days using dipsticks. In parallel, we collected spot urine samples and conducted laboratory measurements of urinary acidity using a pH meter. Unconditional logistic regression was used to estimate associations, adjusting for age, gender, race, Hispanic status, and state. Analyses were further stratified by smoking status.
Results:
Among 616 urothelial carcinoma cases and 897 controls, urine pH consistently≤6.0 was associated with increased bladder cancer risk (Odds Ratio(OR)=1.27; 95% Confidence Interval(CI)=1.02-1.57), with the effect limited to ever-smokers. These findings were supported by analyses of a spot urine, with statistically significant exposure-response relationships for bladder cancer risk overall (p-trend=5.1x10-3) and among ever-smokers (p-trend=1.2x10-3).
Conclusions:
Consistent with a previous study in Spain, our findings suggest that acidic urine pH is associated with increased bladder cancer risk.
Impact:
Our findings align with experimental results showing that acidic urine pH, which is partly modifiable by lifestyle factors, is linked to hydrolysis of acid-labile conjugates of carcinogenic aromatic amines.
Data from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: September 2024

Abstract
Background: Mailed fecal immunochemical test (FIT) outreach can improve colorectal cancer screening rates, yet little is known about how to optimize these programs for effectiveness and cost.

Methods: PROMPT was a pragmatic, stepped-wedge, cluster-randomized effectiveness trial of mailed FIT outreach. Participants in the standard condition were mailed a FIT and received live telephone reminders to return it. Participants in the enhanced condition also received a tailored advance notification (text message or live phone call) and two automated phone call reminders. The primary outcome was six-month FIT completion; secondary outcomes were any CRC screening completion at six months, implementation, and program costs.

Results: The study included 27,585 participants (80% ages 50-64, 82% Latino; 68% preferred Spanish). A higher proportion of enhanced participants completed FIT at six months than standard participants, both in intention-to-treat (+2.8%, 95% CI [0.4%, 5.2%]) and per-protocol (limited to individuals who were reached; +16.9%, 95% CI [12.3%, 20.3%]) analyses. Text messages and automated calls were successfully delivered to 91- 100% of participants. The per-patient cost for standard mailed FIT was $10.84. The enhanced program’s text message plus automated call reminder cost an additional $0.66 live phone calls plus an automated call reminder cost an additional $10.82 per patient.

Conclusions: Adding advance notifications and automated calls to a standard mailed FIT program boosted six-month FIT completion rates at a small additional per-patient cost.

Impact: Enhancements to mailed FIT outreach can improve colorectal cancer screening participation. Future research might test the addition of educational video messaging for screening-naïve adults.
Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Ramakrishnan Geethakumari Praveen Ramakrishnan. , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: September 2024

Supplemental Tables and Protocol Description
Supplementary Table S1 from Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Khurana Rimpi , Labadie Brian , Hirz Taghreed , Mei Shenglin , Hasan Raisa , Shafran Jordan , Kelley Anne , Apostolov Eva , Al-Eryani Ghamdan , Harvey Kate , Rameshbabu Srikrishnan , Loyd Mayme , Bynoe Kaela , Drovetsky Catherine , Solanki Ani , Markiewicz Erica , Zamora Marta , Fan Xiaobing , Schürer Stephan , Swarbrick Alexander , Sykes David B. , Patnaik Akash
Published: September 2024

Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.
Supplemental Methods 1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Methods for Supplemental Data
Supplementary Figure S3 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
Authors: Grant Michael J. , Aredo Jacqueline V. , Starrett Jacqueline H. , Stockhammer Paul , van Alderwerelt van Rosenburgh Iris K. , Wurtz Anna , Piper-Valillo Andrew J. , Piotrowska Zofia , Falcon Christina , Yu Helena A. , Aggarwal Charu , Scholes Dylan , Patil Tejas , Nguyen Christina , Phadke Manali , Li Fang-yong , Neal Joel , Lemmon Mark A. , Walther Zenta , Politi Katerina , Goldberg Sarah B.
Published: September 2024

Supplementary Figure S3. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with second or later line osimertinib (T790M+). The point estimate for median progression free survival associated with each mutation is listed to the right of the figure legend.
Supplementary Data 1 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Supplementary Data: Methods and tables.
Figure S7 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Figure S7: Analysis of CD46 expression in correlation with of the [225Ac]DOTA-YS5 uptake and DNA damage. Digital autographs, H &E staining, and immunofluorescence (Rabbit Isotype control+DAPI, CD46 & phospho-γ-H2Ax) of the tumor tissues injected with [225Ac]DOTA-YS5 for day 1, day 2, day 4, and day 7.
Figure S2 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 2: Modest treatment-induced DNA methylation changes in UC tumors.
Figure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 12: HLA-DR and NKG2D abundance on peripheral lymphocytes associate with longer progression free survival.
Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 11: Peripheral immune cells are activated mid-treatment cycle.
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: September 2024

Figure S4. Biodistribution Study
Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: September 2024

Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated
from matched anti-EpCAM vs anti-Trop2 captured CTCs at the same timepoint.
Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: September 2024

Figure S2. Capture Efficiency of Trop-2 Expressing Cell Lines.
Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Authors: Sperger Jamie M. , Helzer Kyle T. , Stahlfeld Charlotte N. , Jiang Dawei , Singh Anupama , Kaufmann Katherine R. , Niles David J. , Heninger Erika , Rydzewski Nicholas R. , Wang Liguo , Wang Liewei , Yang Rendong , Ren Yanan , Engle Jonathan W. , Huang Peng , Kyriakopoulos Christos E. , Slovin Susan F. , Soule Howard R. , Zhao Shuang G. , Kohli Manish , Tagawa Scott T. , Cai Weibo , Dehm Scott M. , Lang Joshua M.
Published: September 2024

Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
Supplementary Table S2 from A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer
Authors: Ding Nan , You A-Bin , Yang Hu , Hu Guo-sheng , Lai Chun-Ping , Liu Wen , Ye Feng
Published: September 2024

Table S2: Sequence information for probes and primers used in this article.
Supplemental Figure 6 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor
Authors: Rossi Ferdinand , Liu Mengyuan , Tieniber Andrew , Etherington Mark S. , Hanna Andrew , Vitiello Gerardo A. , Param Nesteene J. , Do Kevin , Wang Laura , Antonescu Cristina R. , Zeng Shan , Zhang Jennifer Q. , DeMatteo Ronald P.
Published: September 2024

Supplemental Figure 6.
Cell survival of GIST T1 cells treated with imatinib or avapritinib for 72h in complete media.
Each data point represents an average of 10 wells.
Supplemental Figure 2 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor
Authors: Rossi Ferdinand , Liu Mengyuan , Tieniber Andrew , Etherington Mark S. , Hanna Andrew , Vitiello Gerardo A. , Param Nesteene J. , Do Kevin , Wang Laura , Antonescu Cristina R. , Zeng Shan , Zhang Jennifer Q. , DeMatteo Ronald P.
Published: September 2024

Supplemental Figure 2. GIST PDGFRA D842V PDXs are not sensitive to imatinib.
Supplementary Table S2 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Authors: Liam Chong Kin , Ahmad Azura Rozila , Hsia Te-Chun , Zhou Jianying , Kim Dong-Wan , Soo Ross Andrew. , Cheng Ying , Lu Shun , Shin Sang Won , Yang James Chi-Hsin , Zhang Yiping , Zhao Jun , Berghoff Karin , Bruns Rolf , Johne Andreas , Wu Yi-Long
Published: September 2024

Representativeness of study population
Supplementary Table S2 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Authors: Rotow Julia , Patel Jyoti D. , Hanley Matthew P. , Yu Helena , Awad Mark , Goldman Jonathan W. , Nechushtan Hovav , Scheffler Matthias , Kuo Chih-Hsi S. , Rajappa Senthil , Harada Guilherme , Clifford Sarah , Santucci Alison , Silva Laura , Tupper Rebecca , Oxnard Geoffrey R. , Kherani Jennifer , Drilon Alexander
Published: September 2024

Prior tyrosine kinase inhibitor (TKI) therapy details
Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Per patient ctDNA fractions and PSA levels at baseline and after 4 weeks of treatment
Table S2 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O’Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: September 2024

Summary of anti-tumor activity endpoints in patients treated with eganelisib monotherapy and
combination therapy
Methodology and Criteria for MDSCs 2 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O’Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: September 2024

Study IPI-549-01 methodology and criteria for assessing MDSCs
Supplementary Table S1 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial
Authors: Joensuu Heikki , Wardelmann Eva , Eriksson Mikael , Reichardt Annette , Sundby Hall Kirsten , Schütte Jochen , Cameron Silke , Hohenberger Peter , Sihto Harri , Jost Philipp J. , Lindner Lars H. , Bauer Sebastian , Nilsson Bengt , Kallio Raija , Pesonen Tommi , Reichardt Peter
Published: September 2024

Representativeness of Study Participants
Supplementary Table S3 from Collagen-anchored interleukin-2 and interleukin-12 safely reprogram the tumor microenvironment in canine soft tissue sarcomas
Authors: Stinson Jordan A. , Sheen Allison , Momin Noor , Hampel Jordan , Bernstein Rebecca , Kamerer Rebecca , Fadl-Alla Bahaa , Samuelson Jonathan , Fink Elizabeth , Fan Timothy M. , Wittrup K. Dane
Published: September 2024

Soft tissue sarcoma canine patient information
Supplementary Figure S5 from Collagen-anchored interleukin-2 and interleukin-12 safely reprogram the tumor microenvironment in canine soft tissue sarcomas
Authors: Stinson Jordan A. , Sheen Allison , Momin Noor , Hampel Jordan , Bernstein Rebecca , Kamerer Rebecca , Fadl-Alla Bahaa , Samuelson Jonathan , Fink Elizabeth , Fan Timothy M. , Wittrup K. Dane
Published: September 2024

PAX5 immunohistochemistry
Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Authors: Fathi Amir T. , Kim Haesook T. , Soiffer Robert J. , Levis Mark J. , Li Shuli , Kim Annette S. , DeFilipp Zachariah , El-Jawahri Areej , McAfee Steve L. , Brunner Andrew M. , Amrein Philip C. , Mims Alice S. , Knight Laura W. , Kelley Devon , Bottoms AJ S. , Perry Lindsey H. , Wahl Jonathan L. , Brock Jennifer , Breton Elayne , Marchione Dylan M. , Ho Vincent T. , Chen Yi-Bin
Published: September 2024

Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
Figure S3 from Proteostasis modulation in germline missense von Hippel Lindau disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: September 2024

Figure S3
Figure S2 from Proteostasis modulation in germline missense von Hippel Lindau disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: September 2024

Figure S2
Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Authors: Antoniotti Carlotta , Boccaccino Alessandra , Seitz Robert , Giordano Mirella , Catteau Aurélie , Rossini Daniele , Pietrantonio Filippo , Salvatore Lisa , McGregor Kimberly , Bergamo Francesca , Conca Veronica , Leonetti Simone , Morano Federica , Papiani Giorgio , Tamburini Emiliano , Bensi Maria , Murgioni Sabina , Ross Douglas Teller. , Passardi Alessandro , Boquet Isabelle , Nielsen Tyler J. , Galon Jerome , Varga Matthew Gordon. , Schweitzer Brock L. , Cremolini Chiara
Published: September 2024

Consort diagram of the study.
Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Supplementary Table1 from Somatic exonic deletions in RUNX1 constitutes a novel recurrent genomic abnormality in acute myeloid leukemia
Authors: Eriksson Anna , Engvall Marie , Mathot Lucy , Österroos Albin , Rippin Martin , Cavelier Lucia , Ladenvall Claes , Baliakas Panagiotis
Published: September 2024

Supplementary Table1
Supplementary Table 2 from Somatic exonic deletions in RUNX1 constitutes a novel recurrent genomic abnormality in acute myeloid leukemia
Authors: Eriksson Anna , Engvall Marie , Mathot Lucy , Österroos Albin , Rippin Martin , Cavelier Lucia , Ladenvall Claes , Baliakas Panagiotis
Published: September 2024

Supplementary Table 2
Supplementary Table S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Authors: Tomasich Erwin , Steindl Ariane , Paiato Christina , Hatziioannou Teresa , Kleinberger Markus , Berchtold Luzia , Puhr Rainer , Hainfellner Johannes A. , Müllauer Leonhard , Widhalm Georg , Eckert Franziska , Bartsch Rupert , Heller Gerwin , Preusser Matthias , Berghoff Anna Sophie.
Published: September 2024

Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (Luminal cohort)
Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Authors: Tomasich Erwin , Steindl Ariane , Paiato Christina , Hatziioannou Teresa , Kleinberger Markus , Berchtold Luzia , Puhr Rainer , Hainfellner Johannes A. , Müllauer Leonhard , Widhalm Georg , Eckert Franziska , Bartsch Rupert , Heller Gerwin , Preusser Matthias , Berghoff Anna Sophie.
Published: September 2024

Immune cell infiltration in BM of the three subtypes of BCa: Luminal (A), HER2-positive (B) and Triple-negative breast cancer (TNBC) (C).
Table S8 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Genes enriched in NEAT1-high macrophages
Table S6 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Glioblastoma patient characteristics (DFCI)
Table S3 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

LncRNA transcriptome analysis in melanoma (GSE78220)
Supplementary Fig. 6 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Supplementary Fig. 6 NEAT1 expression in tumor-associated macrophages is associated with TNF-alpha signaling.
Supplementary Figure S6 from Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: September 2024

Antibody array detection of cytokines and chemokines
Supplementary Table S7 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Table S7. Distribution of clinical and biomarker-related characteristics between Methylation Hypoxia High vs Low in the TCGA-pancancer cohort
Supplementary Table S6 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Table S6. Contingency Table of Hypoxia-M and CD8-immunohistochemistry (IHC) staining for CD8-T cells
Supplementary Table S5 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Table S5. Distribution of clinical and biomarker-related characteristics between Methylation Hypoxia High vs Low in the validation cohort (DKTK-ROG)
Supplementary Table S3 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Table S3. Distribution of clinical and biomarker-related characteristics between Methylation Hypoxia High vs Low in the training cohort (TCGA-HNSCC)
Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Authors: Antonarakis Emmanuel S. , Subudhi Sumit K. , Pieczonka Christopher M. , Karsh Lawrence I. , Quinn David I. , Hafron Jason M. , Wilfehrt Helen M. , Harmon Matthew , Sheikh Nadeem A. , Shore Neal D. , Petrylak Daniel P.
Published: September 2024

Supplementary Fig 3 In vivo cellular and humoral responses through 52 weeks are illustrated here.
Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
Authors: Larkin James , Del Vecchio Michele , Mandala Mario , Gogas Helen , Arance Ana M. , Dalle Stephane , Cowey Charles Lance. , Schenker Michael , Grob Jean-Jacques , Chiarion-Sileni Vanna , Marquez-Rodas Ivan , Butler Marcus O. , Di Giacomo Anna Maria , Middleton Mark R. , Lutzky Jose , de la Cruz-Merino Luis , Arenberger Petr , Atkinson Victoria , Hill Andrew G. , Fecher Leslie A. , Millward Michael , Nathan Paul D. , Khushalani Nikhil I. , Queirolo Paola , Ritchings Corey , Lobo Maurice , Askelson Margarita , Tang Hao , Dolfi Sonia , Ascierto Paolo A. , Weber Jeffrey
Published: September 2024

DATA SUPPLEMENT
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
Supplementary Table S1 from Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.
Authors: Blanc-Durand Félix , Tang Roseline , Pommier Margaux , Nashvi Marzieh , Cotteret Sophie , Genestie Catherine , Le Formal Audrey , Pautier Patricia , Michels Judith , Kfoury Maria , Hervé Robert , Mengue Sylvie , Wafo Estelle , Elies Antoine , Miailhe Gregoire , Uzan Jennifer , Rouleau Etienne , Leary Alexandra
Published: September 2024

Primer sequences for methylation analysis (methylation-specific ddPCR)
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Authors: Ailawadhi Sikander , Chen Zi , Huang Bo , Paulus Aneel , Collins Mary C. , Fu Lei (Tommy). , Li Mingyu , Ahmad Mohammad , Men Lichuang , Wang Hengbang , Davids Matthew S. , Liang Eric , Mekala Divya J. , He Zhicong , Lasica Masa , Yannakou Costas K. , Parrondo Ricardo , Glass Laura , Yang Dajun , Chanan-Khan Asher , Zhai Yifan
Published: September 2024

Representativeness of study participants.
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Authors: Ailawadhi Sikander , Chen Zi , Huang Bo , Paulus Aneel , Collins Mary C. , Fu Lei (Tommy). , Li Mingyu , Ahmad Mohammad , Men Lichuang , Wang Hengbang , Davids Matthew S. , Liang Eric , Mekala Divya J. , He Zhicong , Lasica Masa , Yannakou Costas K. , Parrondo Ricardo , Glass Laura , Yang Dajun , Chanan-Khan Asher , Zhai Yifan
Published: September 2024

These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
Supplementary Table S7 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Authors: Leboulleux Sophie , Do Cao Christine , Zerdoud Slimane , Attard Marie , Bournaud Claire , Lacroix Ludovic , Benisvy Danielle , Taïeb David , Bardet Stephane , Terroir-Cassou-Mounat Marie , Anizan Nadege , Bouvier-Morel Emilie , Lamartina Livia , Lion Georges , Betrian Sarah , Sajous Christophe , Schiazza Aurelie , Garcia Marie-Eve , Ciappuccini Renaud , Schlumberger Martin , Al Ghuzlan Abir , Godbert Yann , Borget Isabelle
Published: September 2024

Tissue genotyping
Supplementary Figure S1 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Authors: Leboulleux Sophie , Do Cao Christine , Zerdoud Slimane , Attard Marie , Bournaud Claire , Lacroix Ludovic , Benisvy Danielle , Taïeb David , Bardet Stephane , Terroir-Cassou-Mounat Marie , Anizan Nadege , Bouvier-Morel Emilie , Lamartina Livia , Lion Georges , Betrian Sarah , Sajous Christophe , Schiazza Aurelie , Garcia Marie-Eve , Ciappuccini Renaud , Schlumberger Martin , Al Ghuzlan Abir , Godbert Yann , Borget Isabelle
Published: September 2024

Waterfall plot of the RECIST response
Supplemental Table S3 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand. , Madhusudanannair Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: September 2024

Exosome (50-120nm N=24) PFS Analysis Proportional Hazard Model with Adjustment for Study Arm
Supplemental Figure S1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand. , Madhusudanannair Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: September 2024

CONSORT flow diagram with patient disposition and treatment
Supplementary Table S2 from First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma
Authors: Duan Xiaojiang , Xia Lei , Zhang Zhuochen , Ren Yanan , Pomper Martin G. , Rowe Steven P. , Li Xuesong , Li Nan , Zhang Ning , Zhu Hua , Yang Zhi , Sheng Xinan , Yang Xing
Published: September 2024

Information of healthy subjects and urothelial carcinoma patients enrolled in PET/CT imaging studies using 68Ga-N188 and 18F-FDG
Supplementary Figures S1-S15 from First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma
Authors: Duan Xiaojiang , Xia Lei , Zhang Zhuochen , Ren Yanan , Pomper Martin G. , Rowe Steven P. , Li Xuesong , Li Nan , Zhang Ning , Zhu Hua , Yang Zhi , Sheng Xinan , Yang Xing
Published: September 2024

Figure S1. Synthesis of N188. Figure S2. Mass spectrometry characterization of N188.Figure S3. SPR characterization of N188.Figure S4. Radio-HPLC characterization of 68Ga-N188.Figure S5. Stability of 68Ga-N188 in serum and normal saline. Figure S6. Synthesis of FITC-N188. Figure S7. Mass spectrometry characterization of FITC-N188. Figure S8. Blood routine safety test. Figure S9. Toxicity test of 68Ga-N188. Figure S10. Results of PET/CT dynamic imaging studies in one healthy subject. Figure S11. Pharmacokinetics of 68Ga-N188 in mouse blood. Figure. S12 68Ga-N188 PET/CT imaging with maximum intensity projection (MIP) reconstruction of 12 advanced UC patients with obtained pathological sections. Figure S13. Representative PET/CT images of a patient (No. 3) with advanced urothelial carcinoma. Figure. S14 Comparison of brain metastasis imaging of patient No. 4 using 68Ga-N188, 18F-FDG PET/CT and MRI. Figure. S15 Nectin-4 IHC staining in 12 mUC patients with pathological sections of primary focus.
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Authors: Wethington Stephanie L. , Shah Payal D. , Martin Lainie , Tanyi Janos L. , Latif Nawar , Morgan Mark , Torigian Drew A. , Rodriguez Diego , Smith Simon A. , Dean Emma , Domchek Susan M. , Drapkin Ronny , Shih Ie-Ming , Brown Eric J. , Hwang Wei-Ting , Armstrong Deborah K. , Gaillard Stephanie , Giuntoli Robert , Simpkins Fiona
Published: September 2024

Representativeness of Study Participants
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Authors: Wethington Stephanie L. , Shah Payal D. , Martin Lainie , Tanyi Janos L. , Latif Nawar , Morgan Mark , Torigian Drew A. , Rodriguez Diego , Smith Simon A. , Dean Emma , Domchek Susan M. , Drapkin Ronny , Shih Ie-Ming , Brown Eric J. , Hwang Wei-Ting , Armstrong Deborah K. , Gaillard Stephanie , Giuntoli Robert , Simpkins Fiona
Published: September 2024

Trial schema
Supplementary Table 6 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: September 2024

Supplementary Table 6. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
Supplementary Table 2 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: September 2024

Supplementary Table 2. List of potential ATM germline variants identified among 3800 patients with NSCLC at the DFCI